Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting

   Lilly to Present Data Across its Diabetes Portfolio at the 49th European
             Association for the Study of Diabetes Annual Meeting

Company to showcase late-stage pipeline, including efficacy, safety and
patient-reported health outcomes data for investigational GLP-1 receptor
agonist

PR Newswire

INDIANAPOLIS, Sept. 17, 2013

INDIANAPOLIS, Sept. 17, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
today announced that a total of 31 abstracts will be presented at the 49^th
European Association for the Study of Diabetes Annual Meeting in Barcelona,
September 23-27. In seven presentations, Lilly will share Phase III data for
dulaglutide, its investigational GLP-1 receptor agonist, and Phase II data for
LY2605541, its investigational novel basal insulin analog.

Seventeen abstracts will be presented by Boehringer Ingelheim on behalf of the
Alliance with Lilly.

Lilly will present an additional seven abstracts, including research from its
early-stage pipeline. Lilly's pipeline comprises nearly a dozen potential new
medicines for the treatment of diabetes and its related conditions,
encompassing both large and small molecules, and targeting a variety of
mechanisms.

Following are details on some of the presentations from Lilly's late-stage
pipeline.

Dulaglutide Data
Six dulaglutide abstracts will be presented, including efficacy, safety and
health outcomes data from the Phase III programme. One of these abstracts will
be given as an oral presentation. Details for the presentations are as
follows:

  oTuesday, 24 September 2013, 10:45-12:15 CEST, Oral Presentation

       oEfficacy and safety of dulaglutide vs metformin in type 2 diabetes
         (AWARD-3) (Santiago Tofe Povedano) [Presentation 4]

  oTuesday, 24 September 2013, 13:45-14:45 CEST, General Poster Session

       oDose-finding results in an adaptive trial of dulaglutide combined
         with metformin in type 2 diabetes (AWARD-5) (Zachary Skrivanek)
         [Poster No. 1003]

  oThursday, 26 September 2013, 13:45-14:45 CEST, General Poster Session

       oEfficacy and safety of dulaglutide versus placebo and exenatide in
         type 2 diabetes (AWARD-1) (Carol Wysham) [Poster No. 919]
       oSafety and efficacy of dulaglutide vs sitagliptin after 104 weeks in
         type 2 diabetes (AWARD-5) (Bruno Guerci) [Poster No. 920]
       oEfficacy and safety of dulaglutide vs sitagliptin after 52 weeks in
         type 2 diabetes (AWARD-5) (Michael Nauck) [Poster No. 921]
       oPatient-reported outcomes with dulaglutide, exenatide, or placebo
         (AWARD-1) (Kate Van Brunt) [Poster No. 985]

Novel Basal Insulin Analog (LY2605541) Data
One Phase II abstract will be presented for LY2605541. Details for the
presentation are as follows:

  oThursday, 26 September 2013, 12:30-13:30 CEST, General Poster Session

       oLY2605541 exhibits a flatter glucodynamic profile than insulin
         glargine at steady state in subjects with type 1 diabetes (Linda
         Morrow) [Poster No. 1030]

About Diabetes
Approximately 25.8 million Americans^1 and an estimated 371 million people^2
worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common
type, accounting for an estimated 90 to 95 percent of all diabetes cases.
Diabetes is a chronic disease that occurs when the body either does not
properly produce, or use, the hormone insulin.^3

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced
the world's first commercial insulin. Today we work to meet the diverse needs
of people with diabetes through research and collaboration, a broad and
growing product portfolio and our continued commitment to providing real
solutions — from medicines to support programs and more — to make lives
better. For more information, visit www.lillydiabetes.com.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, IN, Lilly provides answers —
through medicines and information — for some of the world's most urgent
medical needs. Additional information about Lilly is available at
www.lilly.com.

P-LLY

This press release contains forward-looking statements about two
investigational compounds, dulaglutide and novel basal insulin LY2605541,
which are currently in development for the treatment of diabetes. It reflects
Lilly's current beliefs; however, as with any such undertaking, there are
substantial risks and uncertainties in the process of drug development and
commercialization. There is no guarantee that future study results and patient
experience will be consistent with study findings to date or that dulaglutide
and/or novel basal insulin LY2605541 will receive required regulatory
approvals or prove to be commercially successful. For further discussion of
these and other risks and uncertainties, please see Lilly's latest Forms 10-Q
and 10-K filed with the U.S. Securities and Exchange Commission. Lilly
undertakes no duty to update forward-looking statements.

^1 Centers for Disease Control. National Diabetes Fact Sheet-2011. Available
at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed on: February
22, 2012.
^2 International Diabetes Federation. Diabetes Atlas, 5th Edition: Fact Sheet.
2012.
^3 International Diabetes Federation. Diabetes Atlas, 5th Edition: What is
Diabetes? http://www.idf.org/diabetesatlas/5e/what-is-diabetes. Accessed on:
February 22, 2012.

Refer to: Candace Johnson (for dulaglutide inquiries), +1-317-755-9143, 
johnson_candace_a@lilly.com
Tamara Hull (for novel basal insulin inquiries), +1-317-651-9116,
hull_tamara@lilly.com

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

SOURCE Eli Lilly and Company

Website: http://www.lilly.com